Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

OptimizeRx Corporation - Common Stock (NQ: OPRX )

6.640 +0.350 (+5.56%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 190,388
Open 6.340
Bid (Size) 6.450 (1)
Ask (Size) 7.380 (1)
Prev. Close 6.290
Today's Range 6.242 - 6.690
52wk Range 3.780 - 16.64
Shares Outstanding 17,618,607
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Where OptimizeRx Stands With Analysts
Via Benzinga
CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga

Performance

YTD
+27.45%
+27.45%
1 Month
+36.63%
+36.63%
3 Month
+58.10%
+58.10%
6 Month
-21.42%
-21.42%
1 Year
-57.97%
-57.97%

More News

Read More
OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO
From OptimizeRx Corporation
Via GlobeNewswire
The Analyst Verdict: OptimizeRx In The Eyes Of 6 Experts
Via Benzinga
OptimizeRx to Participate in Upcoming Investor Conferences
From OptimizeRx Corporation
Via GlobeNewswire
Earnings Scheduled For November 13, 2024
Via Benzinga
Preview: OptimizeRx's Earnings
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
OptimizeRx Reports Third Quarter 2024 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
A Closer Look at 5 Analyst Recommendations For OptimizeRx
Via Benzinga
Critical Insights From OptimizeRx Analyst Ratings: What You Need To Know
Via Benzinga
OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences
From OptimizeRx Corporation
Via GlobeNewswire
OPRX Stock Earnings: OptimizeRx Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
OptimizeRx Reports Second Quarter 2024 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Delivers AI-Guided Privacy-Compliant Platform for Pharmaceutical Brand Marketing Amid Evolving Consumer Privacy Legislation
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Demonstrates Measurable Script Lift for a Major Depressive Disorder Brand Targeting Physicians of Hard-to-Reach Patients
From OptimizeRx Corporation
Via GlobeNewswire
New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations
From OptimizeRx Corporation
Via GlobeNewswire
Gold Rises Over 1%; Arcos Dorados Shares Fall After Q1 Results
Via Benzinga
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Surges 150 Points; Retail Sales Flat For April
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.